Search

Your search keyword '"Rohde, Luis E."' showing total 126 results
Start Over Author "Rohde, Luis E." Publication Year Range Last 10 years
126 results on '"Rohde, Luis E."'

3. Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials

Author

Furtado, Remo H.M., Barros e Silva, Pedro G.M., Fonseca, Henrique A.R., Serpa-Neto, Ary, Correa, Thiago D., Guimarães, Hélio P., Pereira, Adriano J., Olivato, Guilherme B., Zampieri, Fernando G., Lisboa, Thiago, Junqueira, Debora L.M., Lapa, Maura G., Monfardini, Frederico, Damiani, Lucas P., Echenique, Leandro S., Gebara, Otavio E., Hoffman Filho, Conrado R., Polanczyk, Carisi A, Rohde, Luis E., Amazonas, Roberto, Machado, Flávia R., Avezum, Alvaro, Azevedo, Luciano C.P., Veiga, Viviane C., Rosa, Regis G., Lopes, Renato D., Cavalcanti, Alexandre B., and Berwanger, Otavio

Published
2024
Full Text
View/download PDF

7. Rational and design of a randomized, double-blind, multicenter trial to evaluate the safety and tolerability of furosemide withdrawal in stable chronic outpatients with heart failure: The ReBIC-1 trial

Author

da Rosa, Priscila Raupp, Rohde, Luis E., Doebber, Madeni, Ribeiro, Antonio L.P., Prado, Deborah P., Bertoldi, Eduardo G., Figueiredo Neto, Jose A., Kohler, Ilmar, Beck-da-Silva, Luis, Danzmann, Luiz C., Moura, Lidia Zytynski, Rover, Marciane, Simões, Marcus V., Sant'Anna, Roberto T., and Biolo, Andréia

Published
2017
Full Text
View/download PDF

9. Multifaceted Strategy Based on Automated Text Messaging After a Recent Heart Failure Admission: The MESSAGE-HF Randomized Clinical Trial.

Author

Rohde, Luis E., Rover, Marciane M., Hoffmann Filho, Conrado R., Rabelo-Silva, Eneida Rejane, Silvestre, Odilson M., Martins, Silvia M., Passos, Luiz C. S., de Figueiredo Neto, José A., Danzmann, Luiz C., Silveira, Fábio S., Mesas, Cezar Eumann, Hernandes, Mauro E., Moura, Lidia Z., Simões, Marcus V., Ritt, Luiz E. F., Nishijuka, Fábio Akio, Bertoldi, Eduardo G., Dall Orto, Frederico T. C., Magedanz, Ellen Hettwer, and Mourilhe-Rocha, Ricardo

Published
2024
Full Text
View/download PDF

11. Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure

Author

Rohde, Luis E., primary, Zimerman, André, additional, Vaduganathan, Muthiah, additional, Claggett, Brian L., additional, Packer, Milton, additional, Desai, Akshay S., additional, Zile, Michael, additional, Rouleau, Jean, additional, Swedberg, Karl, additional, Lefkowitz, Martin, additional, Shi, Victor, additional, McMurray, John J. V., additional, and Solomon, Scott D., additional

Published
2023
Full Text
View/download PDF

12. Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction

Author

Curtain, James P, primary, Adamson, Carly, additional, Kondo, Toru, additional, Butt, Jawad Haider, additional, Desai, Akshay S, additional, Zannad, Faiez, additional, Rouleau, Jean L, additional, Rohde, Luis E, additional, Kober, Lars, additional, Anand, Inder S, additional, van Veldhuisen, Dirk J, additional, Zile, Michael R, additional, Lefkowitz, Martin P, additional, Solomon, Scott D, additional, Packer, Milton, additional, Petrie, Mark C, additional, Jhund, Pardeep S, additional, and McMurray, John J V, additional

Published
2023
Full Text
View/download PDF

14. NYHA classification for decision‐making in heart failure: Time to reassess?

Author

Zimerman, André, da Silveira, Anderson D., Solomon, Scott D., and Rohde, Luis E.

Subjects
HEART failure, BRAIN natriuretic factor, LEFT ventricular dysfunction
Abstract

The time-honoured New York Heart Association (NYHA) classification was first described in 1921 as a simple way to categorize patients with heart disease based on symptoms and limitations on physical activity.[1] It evolved over time but preserved its original four categories wherein asymptomatic patients without limitation on ordinary physical activity are classified as NYHA class I, while patients who feel different levels of discomfort with progressive physical activity are categorized as NYHA classes II, III, and IV. Comparing New York Heart Association class and patient-reported outcomes among patients hospitalized for heart failure. Recent advances in HF treatment, particularly for patients with reduced ejection fraction (HFrEF), have substantially improved quality of life and overall survival.[4] However, not all patients with HFrEF are eligible for novel therapies. [Extracted from the article]

Published
2023
Full Text
View/download PDF

15. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF

Author

Curtain, James P., Jackson, Alice, Shen, Li, Jhund, Pardeep S., Docherty, Kieran F., Petrie, Mark C., Castagno, Davide, Desai, Akshay S., Rohde, Luis E., Lefkowitz, Martin P., Rouleau, Jean-Lucien, Zile, Michael R., Solomon, Scott D., Swedberg, Karl, Packer, Milton, and McMurray, John J.V.

Subjects
cardiovascular system, cardiovascular diseases
Abstract

Background:\ud Sudden death is a leading cause of mortality in HFrEF. In PARADIGM-HF, sacubitril/valsartan reduced the incidence of sudden death. The purpose of this post hoc study was to analyze the effect of sacubitril/valsartan, compared to enalapril, on the incidence of ventricular arrhythmias.\ud \ud Methods:\ud Adverse event reports related to ventricular arrhythmias were examined in PARADIGM-HF. The effect of randomized treatment on two arrhythmia outcomes was analyzed: ventricular arrhythmias and the composite of a ventricular arrhythmia, ICD shock or resuscitated cardiac arrest. The risk of death related to a ventricular arrhythmia was examined in time-updated models. The interaction between heart failure aetiology, or baseline ICD/CRT-D use, and the effect of sacubitril/valsartan was analyzed.\ud \ud Results:\ud Of the 8399 participants, 333 (4.0%) reported a ventricular arrhythmia and 372 (4.4%) the composite arrhythmia outcome. Ventricular arrhythmias were associated with higher mortality. Compared with enalapril, sacubitril/valsartan reduced the risk of a ventricular arrhythmia [HR 0.76 (0.62–0.95); p = 0.015] and the composite arrhythmia outcome [HR 0.79 (0.65–0.97); p = 0.025]. The treatment effect was maintained after adjustment and accounting for the competing risk of death. Baseline ICD/CRT-D use did not modify effect of sacubitril/valsartan, but aetiology did: HR in patients with an ischaemic aetiology 0.93 (0.71–1.21) versus 0.53 (0.37–0.78) in those without an ischaemic aetiology (p for interaction = 0.020).\ud \ud Conclusions:\ud Sacubitril/valsartan reduced the incidence of investigator-reported ventricular arrhythmias in patients with HFrEF. This effect may have been greater in patients with a non-ischaemic aetiology.

Published
2022

19. Design of a multifaceted strategy based on automated text messaging in patients with recent heart failure admission

Author

Rohde, Luis E., primary, Hoffmann Filho, Conrado R., additional, Rover, Marciane M., additional, Rabelo‐Silva, Eneida Rejane, additional, Lopez, Letícia, additional, Passos, Luiz C.S., additional, Silvestre, Odilson M., additional, Martins, Silvia M., additional, Figueiredo Neto, José A., additional, Silveira, Fábio S., additional, Canesin, Manoel F., additional, Simões, Marcus V., additional, Akio Nishijuka, Fábio, additional, Bertoldi, Eduardo G., additional, Danzmann, Luiz C., additional, Mourilhe‐Rocha, Ricardo, additional, Magedanz, Ellen Hettwer, additional, Esteves, Mauro, additional, Castilho, Fábio M., additional, Fernandes‐Silva, Miguel M., additional, Ritt, Luiz E.F., additional, Blacher, Mariana, additional, Soares, Rafael M., additional, Cavalcanti, Alexandre B., additional, and Ramirez, Felix, additional

Published
2021
Full Text
View/download PDF

20. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan:Insights from a Combined PARAGON-HF and PARADIGM-HF Analysis

Author

Rohde, Luis E., Claggett, Brian L., Wolsk, Emil, Packer, Milton, Zile, Michael, Swedberg, Karl, Rouleau, Jean, Pfeffer, Marc A., Desai, Akshay S., Lund, Lars H., Køber, Lars, Anand, Inder, Merkely, Bela, Senni, Michele, Shi, Victor, Rizkala, Adel, Lefkowitz, Martin, McMurray, John J.V., Solomon, Scott D., Rohde, Luis E., Claggett, Brian L., Wolsk, Emil, Packer, Milton, Zile, Michael, Swedberg, Karl, Rouleau, Jean, Pfeffer, Marc A., Desai, Akshay S., Lund, Lars H., Køber, Lars, Anand, Inder, Merkely, Bela, Senni, Michele, Shi, Victor, Rizkala, Adel, Lefkowitz, Martin, McMurray, John J.V., and Solomon, Scott D.

Abstract

Background: The net clinical benefit of cardiac disease-modifying drugs might be influenced by the interaction of different domains of disease burden. We assessed the relative contribution of cardiac, comorbid, and demographic factors in heart failure (HF) and how their interplay might influence HF prognosis and efficacy of sacubitril/valsartan across the spectrum of left ventricular ejection fraction. Methods: We combined data from 2 global trials that evaluated the efficacy of sacubitril/valsartan compared with a renin-Angiotensin antagonist in symptomatic HF patients (PARADIGM-HF [Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure; n=8399] and PARAGON-HF [Prospective Comparison of Angiotensin-Converting Enzyme Inhibitor With Angiotensin Receptors Blockers Global Outcomes in Heart Failure With Preserved Ejection Fraction; n=4796]). We decomposed the previously validated Meta-Analysis Global Group in Chronic Heart Failure risk score into cardiac (left ventricular ejection fraction, New York Heart Association class, blood pressure, time since HF diagnosis, HF medications), noncardiac comorbid (body mass index, creatinine, diabetes, chronic obstructive pulmonary disease, smoking), and demographic (age, gender) categories. Based on these domains, an index representing the balance of cardiac to noncardiac comorbid burden was created (cardiac-comorbid index). Clinical outcomes were time to first HF hospitalization or cardiovascular deaths and all-cause mortality. Results: Higher scores of the cardiac domain were observed in PARADIGM-HF (10 [7-13] versus 5 [3-6], P<0.001) and higher scores of the demographic domain in PARAGON-HF (10 [8-13] versus 5 [2-9], P<0.001). In PARADIGM-HF, the contribution of the cardiac domain to clinical outcomes was greater than the noncardiac domain (P<0.001), while in PARAGON-HF the attributable

Published
2021

22. Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM‐HF analysis

Author

Rohde, Luis E., primary, Vaduganathan, Muthiah, additional, Claggett, Brian L., additional, Polanczyk, Carisi A., additional, Dorbala, Pranav, additional, Packer, Milton, additional, Desai, Akshay S., additional, Zile, Michael, additional, Rouleau, Jean, additional, Swedberg, Karl, additional, Lefkowitz, Martin, additional, Shi, Victor, additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2021
Full Text
View/download PDF

23. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan

Author

Rohde, Luis E., primary, Claggett, Brian L., additional, Wolsk, Emil, additional, Packer, Milton, additional, Zile, Michael, additional, Swedberg, Karl, additional, Rouleau, Jean, additional, Pfeffer, Marc A., additional, Desai, Akshay S., additional, Lund, Lars H., additional, Kober, Lars, additional, Anand, Inder, additional, Merkely, Bela, additional, Senni, Michele, additional, Shi, Victor, additional, Rizkala, Adel, additional, Lefkowitz, Martin, additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2021
Full Text
View/download PDF

24. Reply

Author

Solomon, Scott D., primary and Rohde, Luis E., additional

Published
2021
Full Text
View/download PDF

26. Revisiting heart failure assessment based on objective measures in NYHA functional classes I and II

Author

Blacher, Mariana, primary, Zimerman, André, additional, Engster, Pedro H B, additional, Grespan, Eduardo, additional, Polanczyk, Carisi A, additional, Rover, Marciane M, additional, Neto, José A de Figueiredo, additional, Danzmann, Luiz C, additional, Bertoldi, Eduardo G, additional, Simões, Marcus Vinicius, additional, Beck-da-Silva, Luis, additional, Biolo, Andréia, additional, and Rohde, Luis E, additional

Published
2020
Full Text
View/download PDF

29. Revisiting heart failure assessment based on objective measures in NYHA functional classes I and II.

Author

Blacher, Mariana, Zimerman, André, Engster, Pedro H. B., Grespan, Eduardo, Polanczyk, Carisi A., Rover, Marciane M., de Figueiredo Neto, José A., Danzmann, Luiz C., Bertoldi, Eduardo G., Vinicius Simões, Marcus, Beck-da-Silva, Luis, Biolo, Andréia, Rohde, Luis E., Neto, José A de Figueiredo, and Simões, Marcus Vinicius

Subjects
HEART failure, PATIENTS' attitudes, PHYSICIANS' attitudes, MEDICAL research, LOGNORMAL distribution, LEFT heart ventricle, RESEARCH, RESEARCH methodology, PATIENTS, PROTEIN precursors, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, PEPTIDE hormones, HEART physiology, STROKE volume (Cardiac output), PEPTIDES
Abstract

Objective: New York Heart Association (NYHA) functional class plays a central role in heart failure (HF) assessment but might be unreliable in mild presentations. We compared objective measures of HF functional evaluation between patients classified as NYHA I and II in the Rede Brasileira de Estudos em Insuficiência Cardíaca (ReBIC)-1 Trial.Methods: The ReBIC-1 Trial included outpatients with stable HF with reduced ejection fraction. All patients had simultaneous protocol-defined assessment of NYHA class, 6 min walk test (6MWT), N-terminal pro-brain natriuretic peptide (NT-proBNP) levels and patient's self-perception of dyspnoea using a Visual Analogue Scale (VAS, range 0-100).Results: Of 188 included patients with HF, 122 (65%) were classified as NYHA I and 66 (35%) as NYHA II at baseline. Although NYHA class I patients had lower dyspnoea VAS Scores (median 16 (IQR, 4-30) for class I vs 27.5 (11-49) for class II, p=0.001), overlap between classes was substantial (density overlap=60%). A similar profile was observed for NT-proBNP levels (620 pg/mL (248-1333) vs 778 (421-1737), p=0.015; overlap=78%) and for 6MWT distance (400 m (330-466) vs 351 m (286-408), p=0.028; overlap=64%). Among NYHA class I patients, 19%-34% had one marker of HF severity (VAS Score >30 points, 6MWT <300 m or NT-proBNP levels >1000 pg/mL) and 6%-10% had two of them. Temporal change in functional class was not accompanied by variation on dyspnoea VAS (p=0.14).Conclusions: Most patients classified as NYHA classes I and II had similar self-perception of their limitation, objective physical capabilities and levels of natriuretic peptides. These results suggest the NYHA classification poorly discriminates patients with mild HF. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

30. Identification of environmental and genetic factors that influence warfarin time in therapeutic range

Author

Botton, Mariana R., primary, Viola, Patrícia P., additional, Meireles, Mariana R., additional, Bruxel, Estela M., additional, Zuchinali, Priccila, additional, Bandinelli, Eliane, additional, Rohde, Luis E., additional, Leiria, Tiago L. L., additional, Salamoni, Joyce Y. Y., additional, Garbin, Arthur P., additional, and Hutz, Mara H., additional

Published
2020
Full Text
View/download PDF

31. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial

Author

Rohde, Luis E, primary, Rover, Marciane M, additional, Figueiredo Neto, Jose A, additional, Danzmann, Luiz C, additional, Bertoldi, Eduardo G, additional, Simões, Marcus V, additional, Silvestre, Odilson M, additional, Ribeiro, Antonio L P, additional, Moura, Lidia Zytynski, additional, Beck-da-Silva, Luis, additional, Prado, Debora, additional, Sant'Anna, Roberto T, additional, Bridi, Leonardo H, additional, Zimerman, André, additional, Raupp da Rosa, Priscila, additional, and Biolo, Andréia, additional

Published
2019
Full Text
View/download PDF

32. Cardiac hypertrophy in mice submitted to a swimming protocol: influence of training volume and intensity on myocardial renin-angiotensin system

Author

Soares, Douglas dos Santos, primary, Pinto, Graziela Hünning, additional, Lopes, Amanda, additional, Caetano, Daniel Sturza Lucas, additional, Nascimento, Thaiane Gomes, additional, Andrades, Michael E., additional, Clausell, Nadine, additional, Rohde, Luis E. Paim, additional, Leitão, Santiago Alonso Tobar, additional, and Biolo, Andreia, additional

Published
2019
Full Text
View/download PDF

33. Age-dependent availability and functionality of bone marrow stem cells in an experimental model of acute and chronic myocardial infarction.

Author

1874735, Ayala-Lugo, Ana, Tavares, Angela, Paz, Ana H., Alegretti, Ana, Miquelito, Ludmila, Bock, Hugo, Giugliani, Roberto, Clausell, Nedine, Cirne-Lima, Elizabeth Obino, Rohde, Luis E., 1874735, Ayala-Lugo, Ana, Tavares, Angela, Paz, Ana H., Alegretti, Ana, Miquelito, Ludmila, Bock, Hugo, Giugliani, Roberto, Clausell, Nedine, Cirne-Lima, Elizabeth Obino, and Rohde, Luis E.

Abstract

The aim of this study was to investigate the effect of aging and timing of left ventricular ischemic injury on the availability and functionality of stem cells. We studied young and aged male inbred Lewis rats that were used as donors of bone marrow mononuclear cells (BM-MNCs), divided in four experimental groups: controls, sham operated, 48 h post-myocardial infarction (MI), and 28 days post-MI. In vitro studies included flow cytometry analysis, hematopoietic colony-forming capacity, and invasion assays of migration capacity. BM-MNCs from these groups were transplanted in female rats after MI induction. Late engraftment was evaluated by real-time PCR of the SRY chromosome. Percentage of CD34+/CD45+(low) cells was similar among different experimental groups in young rats, but was significantly higher in aged animals (p < 0.001), particularly 28 days post-MI. KDR+/CD34+ cells were increased 48 h after MI and decreased 28 days post-MI in young animals, while they were profoundly reduced in the aged group (p < 0.001). Triple staining for CD44+/CD29+/CD71+ cells was similar in different groups of aged rats, but we observed an intense increase 48 h post-MI in young animals. Colony-forming units and cytokine-induced migration were significantly attenuated 28 days after the MI. Late engraftment in infarcted transplanted female hearts was present, but considerably heterogeneous. Finally, recovery of left ventricular systolic function in transplanted female recipients was significantly influenced by donors' BM-MNCs groups (p < 0.01). We have demonstrated that aging and timing of myocardial injury are factors that may act synergistically in determining stem cell availability and function. Such interaction should be considered when planning new cell therapy strategies for acute and chronic ischemic heart disease in the clinical arena.

Published
2019

36. Cardiac hypertrophy in mice submitted to a swimming protocol: influence of training volume and intensity on myocardial renin-angiotensin system.

Author

dos Santos Soares, Douglas, Pinto, Graziela Hünning, Lopes, Amanda, Lucas Caetano, Daniel Sturza, Nascimento, Thaiane Gomes, Andrades, Michael E., Clausell, Nadine, Paim Rohde, Luis E., Tobar Leitão, Santiago Alonso, and Biolo, Andreia

Abstract

Exercise promotes physiological cardiac hypertrophy and activates the renin-angiotensin system (RAS), which plays an important role in cardiac physiology, both through the classical axis [angiotensin II type 1 receptor (AT1R) activated by angiotensin II (ANG II)] and the alternative axis [proto-oncogene Mas receptor (MASR) activated by angiotensin-(1-7)]. However, very intense exercise could have deleterious effects on the cardiovascular system. We aimed to analyze the cardiac hypertrophy phenotype and the classical and alternative RAS axes in the myocardium of mice submitted to swimming exercises of varying volume and intensity for the development of cardiac hypertrophy. Male Balb/c mice were divided into three groups, sedentary, swimming twice a day without overload (T2), and swimming three times a day with a 2% body weight overload (T3), totaling 6 wk of training. Both training groups developed similar cardiac hypertrophy, but only T3 mice improved their oxidative capacity. We observed that T2 had increased levels of MASR, which was followed by the activation of its main downstream protein AKT; meanwhile, AT1R and its main downstream protein ERK remained unchanged. Furthermore, no change was observed regarding the levels of angiotensin peptides, in either group. In addition, we observed no change in the ratio of expression of the myosin heavy chain β-isoform to that of the α-isoform. Fibrosis was not observed in any of the groups. In conclusion, our results suggest that increasing exercise volume and intensity did not induce a pathological hypertrophy phenotype, but instead improved the oxidative capacity, and this process might have the participation of the RAS alternative axis. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

42. Abstract 318: Vitamin E Affects Pathological Cardiac Hypertrophy and MicroRNAs Expression in Mice

Author

Cohen, Carolina R, primary, Martinelli, Nidiane C, additional, Pinto, Graziela H, additional, Phaelante, Amanda, additional, Silvello, Daiane, additional, Recamonde-Mendoza, Mariana, additional, Andrades, Michael E, additional, Clausell, Nadine, additional, Rohde, Luis E, additional, Ashton-Prolla, Patrícia, additional, and Biolo, Andréia, additional

Published
2016
Full Text
View/download PDF

50. Abstract 15008: Results of the Brazilian Get With the Guidelines Program.

Author

Taniguchi, Fabio P, Bernardez-Pereira, Sabrina, Silva, Suzana A, Pinto, Camila P, Morosov, Erica, Weber, Bernardete, Coutinho, Enia L, Passaglia, Luiz G, Ribeiro, Antonio L, Souza Neto, Joao D, Pessoa, Vera L, Montenegro, Sergio, Sobral Filho, Dario C, Rohde, Luis E, Furtado, Mariana V, Albuquerque, Denilson C, Magalhães, Maria E, Pereira, Kleber R, Santos, Sheila, and Rivera, Maria A

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results